Investigational drug · Phase 2
Tebapivat
Also called: AG-946
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelodysplastic Syndromes, Sickle Cell Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Tebapivat"
First trial start
2022
Nov 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tebapivat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
- Sickle Cell Disease
Approved drugs for the same conditions: Myelodysplastic syndromes · Sickle cell disease · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Tebapivat" as an intervention, largest first.
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Active, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT05490446 · 87 participants · Start Nov 7, 2022 · Primary completion Mar 17, 2026
Drug: Tebapivat · For: Myelodysplastic Syndromes
Sites: Lakewood, California; Los Angeles, California; Redlands, California · 45 sites in all
- A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)Active, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT06924970 · 59 participants · Start May 1, 2025 · Primary completion May 12, 2026
Drug: Tebapivat; Tebapivat Matched Placebo · For: Sickle Cell Disease
Sites: Farmington, Connecticut; Washington D.C., District of Columbia; Atlanta, Georgia · 20 sites in all
Agios Pharmaceuticals, Inc.Industry
NCT06745271 · 8 participants · Start Dec 20, 2024 · Primary completion Feb 21, 2025
Drug: [14C]-tebapivat; [13C2,15N3]-tebapivat · For: Healthy Participants
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.
Musallam KM, Andemariam B · Hemoglobin 2026
- Tebapivat: Pharmacokinetic Properties in Preclinical Species and Pharmacodynamic Responses Associated With Pyruvate Kinase Activation in Wild-Type Mice.
Locuson C, Ronseaux S, McVay M · Biopharm Drug Dispos 2026
- Tebapivat Improves Red Cell Deformability and Decreases Sickling in Patients With Sickle Cell Disease: A Phase 1 Trial Substudy.
Xu JZ, Philips BJ, Kiriza NK, et al. · Eur J Haematol 2026
- Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study.
Fattizzo B, Vercellati C, Marcello A, et al. · Am J Hematol 2024
- Structure-Based Design of AG-946, a Pyruvate Kinase Activator.
Liu T, Padyana AK, Judd ET, et al. · ChemMedChem 2024
- Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.
Xu JZ, Vercellotti GM · Hematology Am Soc Hematol Educ Program 2023
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.